Meningioma Clinical Trial
Official title:
Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study
In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been limited to TBI and SAH. The evidence of TXA in brain tumor was scarce. A few case reports support the role of TXA in brain tumor patients with significant intraoperative bleeding and difficult achieving hemostasis. To prove the benefit of TXA for an attenuation of blood loss in brain tumor patients, research with a larger sample size is required. This prospective, randomized double-blind controlled study will be conducted to evaluate the effect of TXA in reducing blood loss and blood transfusion in patients with intracranial meningiomas, diameter > 5 cm in at least 2 dimensions from the latest radiographic findings.
Background and Literature review: 1. Meningioma 2. Coagulation in craniotomy to remove meningioma 3. Bleeding in craniotomy to remove meningioma 4. Tranexamic acid (TXA) 5. Knowledge gap The topics shown above has been reviewed to conduct a prospective randomized double-blind, placebo controlled study. To prove the study hypothesis: Will intraoperative TXA administration in adult patients scheduled for craniotomy to remove large meningioma decrease blood loss? ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04081701 -
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
|
Phase 4 | |
| Recruiting |
NCT03631953 -
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
|
Phase 1 | |
| Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
| Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
| Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A | |
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Completed |
NCT01811524 -
The Etiology and Progression of Brain Tumors
|
N/A | |
| Completed |
NCT03648034 -
Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality
|
N/A | |
| Recruiting |
NCT06036706 -
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
|
N/A | |
| Recruiting |
NCT06014905 -
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
|
Phase 1 | |
| Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
| Completed |
NCT04305470 -
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
|
Phase 3 | |
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02978677 -
Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas
|
N/A | |
| Active, not recruiting |
NCT02933736 -
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
|
Early Phase 1 | |
| Completed |
NCT02267928 -
Information Presentation Formats
|
N/A | |
| Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
| Active, not recruiting |
NCT03071874 -
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
|
Phase 2 | |
| Recruiting |
NCT05416567 -
Embolization for Meningioma
|
N/A | |
| Not yet recruiting |
NCT06126588 -
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
|
Phase 2 |